Galacto-oligosaccharide preparations rich in sialic acid lactose

By separating with macroporous or gel-type anion exchange resins and eluting with acidic salt solutions, combined with demineralization treatment, the problems of difficult control of sialic acid lactose content and high mineral content in existing technologies have been solved, and high-quality oligogalactose preparations rich in sialic acid lactose have been prepared.

CN123124875APending Publication Date: 2026-11-17FRIESLANDCAMPINA NEDERLAND BV
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202580027769.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2024-04-25
Filing Date
2025-04-24
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Existing technologies struggle to effectively control the sialic acid lactose content when preparing galactooligosaccharide formulations rich in sialic acid lactose. Furthermore, the high mineral content of delactose whey permeate complicates the preparation process and makes it difficult to remove color-forming compounds.

Method used

Sialyllactose was separated by using macroporous or gel-type anion exchange resin, followed by elution with acidic salt solution, demineralization treatment, and finally added to or converted into galactooligosaccharide composition, with the sialic acid lactose content controlled at 0.2-3.0 wt%.

Benefits of technology

It enables precise control of sialic acid lactose content, simplifies the preparation process, reduces mineral content and color-forming compounds, and improves the quality of galactooligosaccharide preparations.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

A method for producing galactooligosaccharide formulations rich in sialic acid lactose from whey permeate, the method involving ion removal and chromatography.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This invention relates to the field of nutritional components. More particularly, this invention relates to a method for producing a galactooligosaccharide (GOS) formulation having a relatively high content of oligosaccharides naturally present in milk.

[0002] Various physiological functions of GOS have been reported, including stimulating the growth of Bifidobacteria in the gut, supporting normal intestinal transit, promoting natural defenses, and enhancing mineral absorption. GOS has received particular attention due to its prebiotic effects in promoting the growth of Bifidobacteria, Lactobacillus, and other gut bacteria. Therefore, GOS is commonly used in formula feeding (infant formula, follow-up formula, and toddler formula).

[0003] Galacto-oligosaccharides (GOS) typically consist of chains of galactose units and terminal glucose units produced by a series of transgalactosylation reactions catalyzed by β-galactosidase. Some GOS components are naturally present in human breast milk and bovine colostrum. Typical GOS preparations mainly contain disaccharides to hexasaccharides.

[0004] Typically, GOS is produced from lactose through transglycosylation with β-galactosidase (enzyme EC.3.2.1.23). β-galactosidase is produced in many microorganisms, such as *Bacillus circulans*, *Aspergillus oryzae*, *Kluyveromyces marxianus*, *Kluyveromyces fragilis*, *Sporobolomyces singularis*, *Papiliotrema terrestris*, and *Lactobacillus fermentum*. The different three-dimensional structures of β-galactosidase result in stereoselectivity and regioselectivity in the formation of glycosidic bonds. For example, fungal β-galactosidases derived from the genus *Aspergillus* primarily produce β1-6 bonds (thus generating GOS preparations mainly containing β1-6 bonds, which can be called "6'-GOS"), while bacterial β-galactosidases derived from the genus *Bacillus* primarily produce β1-4 bonds (producing GOS preparations mainly containing β1-4 bonds, which can also be called "4'-GOS"). Furthermore, β-galactosidases produced by *Bacillus circulans* exhibit particularly strong transgalactosylation activity. Therefore, GOS prepared from *Bacillus circulans* β-galactosidases is sold worldwide.

[0005] Lactose, the starting material used in GOS production, is typically derived from milk and obtained through the crystallization of whey ultrafiltration permeate (referred to herein as "whey permeate"). This whey permeate is produced by ultrafiltration of whey. The lactose concentration in this whey permeate is typically in the range of 75–90 wt% on a dry matter basis.

[0006] Whey permeate itself can also be used as a lactose source for GOS production. Lactose-free whey permeate can also be used as a lactose source for galactooligosaccharide production. This lactose-free whey permeate is commonly referred to as DLP or OPL, which is derived from the mother liquor of lactose crystallization, as disclosed in WO 2006 / 087391, WO 2018 / 020473 and WO 2020 / 141032.

[0007] The method disclosed in WO 2006 / 087391 involves enzymatic treatment of a lactose source with β-galactosidase, the lactose source being obtained by concentration of whey permeate, lactose removal (e.g., crystallization) and demineralization (by reverse osmosis, nanofiltration or ion exchange).

[0008] WO 2020 / 141032 also discloses the production of GOS starting from demineralized (e.g., via electrodialysis) lactose-free whey permeate. This is to remove divalent anions like PO4. 3- And citrate, the document proposes adding calcium to precipitate the corresponding calcium salt.

[0009] The method disclosed in WO 2018 / 020473 involves precipitating minerals from lactose-free whey permeate by heat treatment, followed by ultrafiltration and nanofiltration.

[0010] One advantage of using whey permeate as a lactose source is that it allows the utilization of one of the most abundant waste streams in the dairy industry. Another advantage is that the permeate contains a high amount of oligosaccharides naturally present in milk, such as sialyl-lactose, 3'-sialyl-lactose (3'-SL), and 6'-sialyl-lactose (6'-SL), enabling the production of GOS containing these oligosaccharides. These oligosaccharides are also known to have significant health benefits by supporting pathogen resistance, intestinal maturation, immune function, and cognitive development. The commercial production of such sialyl-lactose currently involves fermentation reactions using genetically engineered microorganisms.

[0011] GOS can be added to formula food feeding at a concentration of 2.4-8.0 g / L, preferably 3.0-7.5 g / L, and most preferably 4.0-7.2 g / L.

[0012] The main sialyl lactose 3'-SL in cow's milk can be added to formula feeding at a concentration of up to about 0.3 g / L.

[0013] Therefore, the aim is to provide a GOS formulation containing 0.2–3.0 wt% sialyl lactose based on dry matter, thereby allowing the direct introduction of this GOS formulation into formulated food feeding. If the sialyl lactose content is significantly higher than 3.0 wt%, direct introduction carries the risk of introducing more sialyl lactose than permitted.

[0014] The aforementioned prior art methods require the use of lactose-free whey permeate in order to obtain a sufficiently high sialic acid lactose content in the resulting GOS.

[0015] However, a drawback of lactose-free whey permeate is its high mineral content, which necessitates extensive demineralization and concentration steps. Furthermore, the sialyl lactose content of the final GOS is difficult to control.

[0016] Another disadvantage of using lactose-free whey permeate is that it contains nitrogenous compounds and color-forming compounds that cannot be removed with conventional anion exchange columns without losing sialic acid lactose.

[0017] Therefore, the object of the present invention is to provide a method for preparing galactooligosaccharide formulations rich in sialic acid lactose (SL), such that the SL content can be easily controlled, the aforementioned problems can be overcome, and SL-rich GOS can be introduced into formula feeding.

[0018] This invention relates to a method for producing galactooligosaccharide formulations having at least 35 wt% galactooligosaccharides other than lactose and 0.2-3.0 wt% sialylate content based on dry matter. The method comprises the following steps:

[0019] i) Provide whey permeate with a lactose concentration in the range of 75-90 wt% on a dry matter basis.

[0020] ii) Remove monovalent and polyvalent ions from the whey permeate to obtain a demineralized whey permeate.

[0021] iii) Sialyllactose is separated by subjecting the demineralized whey permeate to a macroporous or gel-type anion exchange resin and subsequently eluting sialyl lactose from the macroporous or gel-type anion exchange resin with an acidic salt solution.

[0022] iv) subject the separated sialic acid lactose to a demineralization step.

[0023] v) Add the demineralized sialylated lactose to an oligogalactose composition containing at least 35 wt% of oligogalactose other than lactose to form the oligogalactose formulation, or add the demineralized sialylated lactose to a lactose source and convert the lactose into oligogalactose using β-galactosidase.

[0024] whey exudate

[0025] The method of the present invention begins with whey permeate, which is the lactose-rich ultrafiltration permeate remaining after protein is concentrated from whey.

[0026] Whey is produced by separating (skimmed) milk into fractions rich in casein and whey protein; through curdling (i.e., cheese making), acidification, or microfiltration. Whey produced from cheese making is called cheese whey; whey produced by acidification is called acid whey; and the permeate produced by microfiltration of milk is called ideal whey.

[0027] Whey protein is typically concentrated by subjecting whey to ultrafiltration. This ultrafiltration typically uses membranes with a molecular weight cutoff (MWCO) in the range of 5-10 kDa. Most of the water, lactose, sialyl lactose, minerals, and vitamins pass through the membrane and form whey permeate, while the protein is retained by the membrane as a whey protein concentrate.

[0028] The whey penetrant used in the method of the present invention can be a cheese whey penetrant, an acidic whey penetrant, or an ideal whey penetrant. Preferably, the whey penetrant is a cheese whey penetrant (CWP) or an acidic whey penetrant. Most preferably, it is a cheese whey penetrant.

[0029] The lactose content of whey permeate is in the range of 75-90 wt%.

[0030] Based on dry solids, the sialic acid lactose content of whey permeate is typically about 0.1-0.3 wt%.

[0031] Demineralization

[0032] The whey permeate is subjected to one or more demineralization steps to remove monovalent and polyvalent ions. The main polyvalent ions are calcium and phosphate ions.

[0033] This demineralization can be performed using electrodialysis, mineral precipitation, ion exchange, and / or nanofiltration. The demineralization step should be carried out in a manner that prevents the removal of significant amounts of sialic acid and lactose from the whey permeate.

[0034] Demineralization preferably produces a whey permeate, which is demineralized to an ash content of about 0.1-5.0 wt%, more preferably 0.1-4.0 wt%, even more preferably 0.1-3.0 wt%, more preferably 0.1-2.0 wt%, and most preferably 0.1-1.0 wt.% based on dry matter.

[0035] In one embodiment, demineralization is carried out by electrodialysis, thereby removing both monovalent and polyvalent ions simultaneously.

[0036] In another embodiment, at least one cation exchange step replaces polyvalent ions with monovalent ions (such as sodium or potassium) to replace calcium ions with monovalent cations, and at least one anion exchange step replaces phosphate ions with monovalent anions (such as chlorides), after which the monovalent ions can be removed by membrane filtration or another ion exchange step.

[0037] In particular, for the anion exchange step, it should be ensured that this step does not result in the removal of large amounts of sialic acid lactose. This can be achieved by using anion exchange resin in chloride form, preferably a gel-type styrene-divinylbenzene or gel-type cross-linked acrylic anion exchange resin having tertiary amine functional groups, more preferably dimethylamine groups.

[0038] Following the ion exchange step, a membrane filtration step is preferably performed using a membrane permeated with monovalent ions (such as sodium, potassium, and chloride) to further demineralize and simultaneously concentrate the whey permeate. Sialyllactose should be retained in the membrane filtration residue.

[0039] During this step, the whey permeate is preferably concentrated to a dry matter content of 10-25 wt%, preferably 15-20 wt%.

[0040] Any membrane suitable for desalination purposes can be used in this step.

[0041] In one embodiment, a nanofiltration membrane with a molecular weight cutoff in the range of 200-300 Da is used. In another preferred embodiment, the membrane is a polypiperazine amide membrane. The nanofiltration is preferably combined with percolation.

[0042] In another preferred embodiment, a membrane with a molecular weight cutoff of 400-2500, preferably 400-2000, more preferably 400-1500, even more preferably 400-1000, even more preferably 400-700, more preferably 400-600, and most preferably 400-500 Daltons is used. Such membranes not only cause demineralization but also result in the removal of some lactose, thereby increasing the sialylate / lactose ratio. This membrane filtration is preferably carried out until the resulting osmotic residue has a lactose content in the range of 90-99.8 wt% of dry matter and a sialylate content relative to lactose in the range of 0.2-3.0 wt%. This membrane filtration can be combined with percolation. Percolation is used to further reduce polyvalent ions (e.g., phosphate) and non-protein nitrogen (NPN). This membrane filtration is preferably carried out at a temperature in the range of 5°C-60°C, preferably 10°C-50°C, and most preferably 40°C-50°C. Since the solubility of lactose increases with temperature, higher filtration temperatures allow for higher lactose concentrations. On the other hand, temperatures in the range of 5°C–15°C, more preferably 5°C–10°C, may be desirable to reduce microbial growth.

[0043] In addition to or as an alternative to membrane filtration, monovalent ions can also be removed via cation and anion exchange steps. In a preferred embodiment, cation exchange is performed prior to anion exchange. Besides removing minerals, this ion exchange can also reduce the non-protein nitrogen (NPN) content of demineralized whey permeate.

[0044] This cation exchange step preferably uses acid in the form of free acid (H+). + The cation exchange material is a strong acid cation exchange resin (in the form of a styrene-divinylbenzene cation exchange resin). The resin is preferably a styrene-divinylbenzene cation exchange resin, more preferably a macroporous or gel-type styrene-divinylbenzene cation exchange resin. In a preferred embodiment, the cation exchange material contains sulfonic acid functional groups. Most preferably, the cation exchange material is a strong acid cation exchange resin having a styrene / divinylbenzene gel-type matrix and sulfonic acid functional groups.

[0045] To prevent sialyl lactose from binding to the anion exchange resin, the anion exchange resin should be a gel-type anion exchange resin (e.g., cross-linked polystyrene-divinylbenzene gel) with a moisture content of 30%-48%, preferably 35%-45%. At lower moisture contents, the demineralization capacity becomes too low; at higher moisture contents, the affinity for sialyl lactose increases. Due to the low moisture content and dense network of the gel-type resin, the migration rate of sialyl lactose is lower than that of the abundant chloride anions. As a result, sialyl lactose will remain in the liquid phase, while chloride anions preferentially bind to the resin.

[0046] Moisture content was determined as follows: Before measuring the moisture content of the resin, adhering water was removed, for example by wrapping the resin in a cloth and then centrifuging it (centrifuge: 30 cm diameter; 3,000 rpm); the resin was then weighed, for example in a weighing bottle; the resin was then dried at a constant temperature of 105°C for 4 hours; the resin was then cooled in a desiccator for 30 minutes; the weight of the dried resin was then determined; Moisture percentage (wt%) = [(weight loss after drying (g)) / (weight of wet resin)] 100%.

[0047] The anion exchange resin preferably has strong anion exchange groups, and more preferably type II anion exchange groups.

[0048] To remove any nonionic organic components and / or undissociated molecules such as nonprotein nitrogen, it may be desirable to pass the demineralized whey permeate through a column of absorbent material. This can be conventional absorbent materials such as activated carbon, but cation exchange materials are preferred. Such cation exchange materials preferably have a macroporous structure, exhibiting higher porosity and lower ionic group density compared to the cation exchange resins mentioned above.

[0049] The porosity of this cation exchange material is preferably in the range of 0.8 to 1.2 ml / g, more preferably 0.9 to 1.1 ml / g, and most preferably 0.95 to 1.05 ml / g. The BET surface area is preferably ≥ 600 m². 2 / g, more preferably ≥ 650m 2 / g, or even more preferably ≥ 670 m 2 / g and the optimal value is ≥ 700 m 2 / g.

[0050] The absorbent material is preferably a styrene / divinylbenzene copolymer matrix, whose hydrophilicity is enhanced by the presence of sulfonic acid groups. In the method of the present invention, it is used to absorb cationic and non-cationic components, typically organic components, particularly non-cationic components, and more particularly components that are neutral at the pH of the solution. Compared to absorbent materials (like activated carbon), such materials have the advantage of inertness in absorbing acidic oligosaccharides.

[0051] Isolation of sialic acid lactose

[0052] The demineralized whey permeate is contacted with a macroporous or gel-type anion exchange resin capable of capturing and binding sialic acid lactose. To enhance effectiveness, the moisture content of the macroporous or gel-type anion exchange resin is greater than 45%, and more preferably between 50% and 70%. Macropores are present in such resins. The resin is preferably in the form of a free base.

[0053] The temperature during this step is preferably below 20°C and more preferably below 10°C.

[0054] Sialactose can then be eluted from the resin using a small volume of acidic salt solution, preferably NaCl, and / or KCl solution acidified with HCl. The acidity of this solution ensures that the pH of the resulting eluent containing sialic acid does not rise above a level that adversely affects the stability of sialic acid. The eluent containing sialic acid preferably has a pH in the range of 3-9, more preferably 4-8, and most preferably 5-6.

[0055] Demineralization of eluents containing sialic acid lactose

[0056] The eluent is then demineralized, preferably by nanofiltration, or preferably by a combination of nanofiltration and percolation.

[0057] If the pH is no longer within that value, the pH of the resulting demineralized eluent should preferably be adjusted to a value in the range of 3-9, more preferably 4-8, and most preferably 5-6.

[0058] Preparation of GOS formulations

[0059] According to one embodiment, isolated and demineralized sialic acid lactose is then added to the galactooligosaccharide composition to form a galactooligosaccharide formulation.

[0060] According to another embodiment, a galactose formulation is obtained by adding isolated and demineralized sialylated lactose to a lactose source, followed by using β-galactosidase to convert the lactose source into galactooligosaccharides.

[0061] The resulting GOS formulation contains at least 35 wt%, preferably 40-90 wt%, and most preferably 50-70 wt% of galactooligosaccharides other than lactose based on dry matter, and 0.2-3.0 wt%, preferably 0.2-2.0 wt%, and most preferably 0.4-1.0 wt% of sialyl lactose.

[0062] Based on the total weight of oligosaccharides other than lactose, the GOS formulation preferably contains 0.2-5.0 wt%, more preferably 0.3-4.0 wt%, more preferably 0.3-3.0 wt%, even more preferably 0.4-2.0 wt%, and most preferably 0.5-1.0 wt% sialylated lactose.

[0063] The sialyl lactose content is mainly composed of 3'-sialyl lactose and 6'-sialyl lactose, and can be determined by chromatography using an Acquity Premier Glycan BEH amide 130A 1.7 µm column and a fluorescence detector. The sialyl lactose content is calculated as the sum of the contents of 3'-sialyl lactose and 6'-sialyl lactose.

[0064] When obtaining a galactose formulation by adding isolated and demineralized sialyl lactose to a lactose source and subsequently converting the lactose source to galacto-oligosaccharides using β-galactosidase, the dry matter content of the lactose source containing isolated and demineralized sialyl lactose is preferably adjusted to at least 35 wt%, preferably at least 40 wt%, more preferably at least 45 wt%, and most preferably at least 50 wt% before conversion to galacto-oligosaccharides. This can be achieved by conventional techniques such as membrane filtration or evaporation. If the dry matter content is already within this range, no further action is required.

[0065] Furthermore, the pH of the lactose source containing isolated and demineralized sialic acid lactose is preferably adjusted to a value in the range of 5-7, preferably 5.5-6.5, and most preferably 6.0-6.3. If the pH is already within this range, no further action is required. If the pH is outside this range, it can be adjusted by adding an acid or base (such as citric acid or NaOH).

[0066] Suitable β-galactosidases for converting lactose into galacto-oligosaccharides include those selected from the group consisting of: Bacillus circulatoryformis, Aspergillus oryzae, Kluyveromyces martensii, Kluyveromyces fragilis, Monotyphimurium, Lactobacillus fermentum, and Cryptococcus papiliotrema terrestris. Preferred enzymes are β-galactosidases produced by Bacillus circulatoryformis.

[0067] The enzymatic conversion is preferably carried out at a temperature of about 20°C-60°C, more preferably 40°C-60°C, and most preferably 45°C-55°C.

[0068] The enzyme is preferably used in an amount of 0.60-2.5 LU / g, more preferably 0.65-2.0 LU / g, and most preferably 0.65-1.1 LU / g. A lactase unit (LU) is defined as the amount of enzyme that releases 1 micromole of glucose per minute at 40°C and pH 6.0 in the early stages of the reaction.

[0069] The enzymatic reaction can proceed for 6-50 hours, preferably 10-48 hours, or even more preferably 18-24 hours, after which the enzyme may denature (e.g., by heating at about 95°C-100°C or adjusting the pH to about 3.5 or lower), and the GOS formulation may be subjected to additional purification and concentration steps to obtain a syrup, which may optionally be dried (e.g., spray dried) to form a powder.

[0070] Enzymes can be used in powder form (e.g., by freeze drying, vacuum drying, or spray drying) or in liquid form (e.g., dissolved or dispersed in water, phosphate buffer, triethanolamine buffer, trihydrochloric acid buffer, or GOOD buffer).

[0071] In certain embodiments, the enzyme is used in an immobilized form. Various methods of enzyme immobilization are known in the art. These typically involve porous carriers on which β-galactosidase is immobilized via covalent bonding, physical adsorption (charge-charge or van der Waals interactions), gel encapsulation, or a combination thereof. Additionally, carrier-free immobilized enzymes, such as CLECs (crosslinked enzyme crystals) or CLEAs (crosslinked enzyme aggregates), can also be used.

[0072] Transporters that can facilitate the direct covalent binding of enzymes are preferred because they are easy to handle and do not leak into the reaction mixture. Examples of solid transporters are activated acrylic polymers, preferably functionalized polymethacrylate matrices. For example, hexamethylene amino-functionalized polymethacrylate matrices (Sepabeads) or microporous acrylic epoxy-activated resins, such as Eupergit C 250L, can be used.

[0073] The use of immobilized enzymes allows for repeated batch operating systems, which involve several consecutive batches (“cycles”) of GOS purification. It also allows for enzyme recycling, enabling semi-continuous operation and multiple reuses of the enzyme.

[0074] In another specific embodiment, the reaction is carried out in an enzymatic membrane reactor.

[0075] The resulting product can be subjected to purification steps, evaporation, and / or (spray) drying. In a preferred embodiment, one of the purification steps involves a decolorization step using a cation exchange resin in free acid form and an absorbent resin as defined above. Besides removing color, this step also helps to further reduce ash content. To prevent the loss of sialyl lactose at this stage, binding to the anion exchange resin should be prevented either by not performing the anion exchange step or by applying an anion exchange step with a resin that does not bind sialyl lactose as discussed above. More preferably, the anion exchange step is not performed at this stage; this not only prevents the introduction of additional anions into the product, but the use of cation exchange in the absence of anion exchange also results in a decrease in the pH of the product, thereby improving microbial stability. The latter thus eliminates the need to add acid to achieve microbial stability.

[0076] application

[0077] The galactooligosaccharide formulation rich in sialic acid lactose produced by the method of the present invention can be used in nutritional compositions for human subjects of any age. In one embodiment, the subject is an adolescent or an adult. An adolescent is defined herein as a person aged 13 to 20 years. An adult is defined herein as a person aged 20 years or older. In another embodiment, the subject is a child aged 3 years (36 months) to 13 years. In yet another embodiment, the subject is a child aged 0 to 3 years, preferably 24 months or younger, more preferably 18 months or younger.

[0078] In one embodiment, the nutritional composition is a MUM composition for pregnant women, growth milk (GUM), subsequent formula food, or infant formula food.

[0079] Such nutritional compositions may further comprise protein sources, digestible carbohydrate sources, and / or lipid sources. Protein sources are known in the art, particularly for use in infant formula, and include dairy proteins (whey protein, casein) and / or plant protein sources (e.g., pea, broad bean, low-erucic acid rapeseed, soy protein). Examples of digestible carbohydrate sources are disaccharides (such as lactose and sugars), monosaccharides (such as glucose and maltodextrin), starch, and carbohydrate sources with prebiotic effects. Suitable lipid sources include monoglycerides, diglycerides, and triglycerides, phospholipids, sphingolipids, fatty acids, and their esters or salts. Lipids may be of animal, plant, microbial, or synthetic origin. Of particular interest are polyunsaturated fatty acids (PUFAs), such as gamma-linolenic acid (GLA), diazolinone (DHGLA), arachidonic acid (AA), octadecanoic acid (SA), eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), docosapentaenoic acid (DPA), and conjugated linoleic acid (CLA). Examples of suitable plant-based lipid sources include sunflower oil, high-oleic sunflower oil, coconut oil, palm oil, palm kernel oil, and soybean oil. Examples of suitable animal-based lipid sources include milk fat, such as anhydrous milk fat (AMF) and butter. In a preferred embodiment, a combination of milk fat and plant-based lipids is used.

[0080] The nutritional composition may further contain probiotics, such as bacteria of the genus *Bifidobacteria* (e.g., *Bifidobacteria breve*, *Bifidobacteria longum*, *Bifidobacteria infantis*, *Bifidobacteria bifidum*), bacteria of the genus *Lactobacillus* (e.g., *Lactobacillus acidophilus*, *Lactobacillus paracasei*, *Lactobacillus johnsonii*, *Lactobacillus plantarum*, *Lactobacillus reuteri*, *Lactobacillus rhamnosus*, *Lactobacillus casei*, *Lactobacillus lactis*), and bacteria of the genus *Streptococcus* (e.g., *Streptococcus thermophilus*). *Bifidobacteria breve* and *Bifidobacteria longum* are particularly suitable probiotics.

[0081] In addition, the composition may contain one or more conventional micro-ingredients, such as vitamins, antioxidants, minerals, free amino acids, nucleotides, taurine, carnitine, and polyamines. Examples of suitable antioxidants are BHT, ascorbyl palmitate, vitamin E, alpha and beta carotene, lutein, zeaxanthin, lycopene, and phospholipids.

[0082] Example

[0083] Cheese whey permeate with a dry matter content of 6.6 wt%, a lactose concentration of 83 wt% on a dry matter basis, and a sialic acid lactose content of 0.2 wt% on a dry matter basis was used as the starting material.

[0084] Demineralize the cheese whey permeate by removing monovalent and polyvalent ions.

[0085] First, multivalent ions were removed by passing the whey permeate at 10°C through a weakly basic anion exchange resin in chloride form (XA3112; with a cross-linked acrylic gel matrix, tertiary amine functional groups, and 56%–64% water retention capacity), followed by passage through a strong acid cation exchange resin in sodium form (XA 2033; with styrene-divinylphenyl, sulfonic acid functional groups, and 43%–45% water retention capacity). This resulted in the exchange of phosphate and calcium ions for chloride and sodium ions, respectively. When approximately 25 bed volumes (BV) of whey permeate were applied, approximately 90% of calcium ions and approximately 50%–60% of phosphate ions were found to be removed.

[0086] The resulting demineralized product was then used with Dow Filmtec. TM Nanofiltration was performed using an NF-2540 membrane (Dow Chemical Company; thin-film poly(piperazine-amide) composite membrane with a molecular weight cutoff greater than 200 Da for organics) to remove monovalent ions. A concentrate was obtained by continuous recycling of the demineralized product over the membrane at 10°C and a transmembrane pressure of 20–25 bar. Consequently, the dry matter content of the concentrate was increased to 17%, and the lactose concentration increased from 83% to 93% (on a dry matter basis).

[0087] The nanofiltration residue (10°C) was then passed through a cation exchange resin in the form of free acid (XA2041 Na; a macroporous strong cation exchange resin with a styrene-divinylbenzene copolymer matrix, SO3 functional group, and 48% ± 6% moisture retention capacity), an anion exchange resin in the form of free base (UBA150; a strong anion exchange resin with a styrene-divinylbenzene matrix, trimethylammonium functional group, and 39%–45% moisture retention capacity), and an absorbent resin (XA5072 H; a styrene-divinylbenzene copolymer matrix, SO3 functional group, and 700 m...). 2 (The average surface area per g and the cation exchange resin with a moisture content of 54% ± 3%).

[0088] The demineralized product at pH 8.9 was subjected to membrane filtration using a 1000 Da membrane at a controlled temperature of 10°C and a pressure of 8 bar.

[0089] This membrane filtration increases the dry matter content from 11.4 wt% to 14.2 wt%, reduces the ash content from 0.74 wt% to 0.03 wt% on a dry matter basis, increases the sialic acid lactose content from 0.18 wt% to 0.6 wt% on a dry matter basis, and increases the lactose content from 95 wt% to 96 wt% on a dry matter basis.

[0090] The effluent is subjected to another anion exchanger in the form of a free base (XA90 CL; with a styrene-divinylbenzene copolymer matrix, -N + A strong-base anion exchange resin with a (CH3)2C2H4OH functional group and a water retention capacity of 54% ± 6% binds virtually all of the sialic acid-lactose. After column rinsing, the bound sialic acid-lactose is recovered by eluting the resin with a 0.2 M NaCl solution. During elution, the pH is neutralized to approximately 5.5 using hydrochloric acid.

[0091] The eluent rich in sialic acid lactose was obtained by using Filmtec. TM Nanofiltration of the NF-2540 membrane (Dow Chemical Company; thin-film poly(piperazine-amide) composite membrane with a molecular weight cutoff greater than 200 Da for organics demineralized and concentrated, allowing monovalent ions to pass through. The concentrate is obtained by continuous recycling of the demineralized product on the membrane at 10°C and a transmembrane pressure of 20–25 bar. Therefore, the dry matter content in the concentrate is increased to 19%.

[0092] The NF osmotic residue rich in sialyl lactose was blended with a 51 wt% demineralized lactose solution at a weight ratio of 7:100 to normalize the sialyl lactose content (on dry matter) to 0.41 wt%.

[0093] The concentrated solution was used to produce GOS via an enzymatic reaction.

[0094] The pH of the solution was set to 6.3 and kept constant by adding citrate buffer during the reaction, along with β-galactosidase (2.7 LU / g) derived from Bacillus circulatoryus. After reacting at 58°C for 42 h, the solution was heated to 130°C to inactivate the enzyme, and the pH of the resulting GOS syrup was adjusted to 3.8 with citric acid.

[0095] GOS syrup was concentrated to 75 wt% dry matter by evaporation.

[0096] It contains 59 wt% galactooligosaccharides other than lactose and 0.51 wt% sialyl lactose; all on a dry matter basis. Ash content is 0.25 wt%.

Claims

1. A method for producing a galactooligosaccharide formulation having at least 35 wt% galactooligosaccharides other than lactose and a sialic acid lactose content in the range of 0.2-3.0 wt% based on dry matter, the method comprising the following steps: i) Provide whey permeate with a lactose concentration in the range of 75-90 wt% on a dry matter basis. ii) Remove monovalent and polyvalent ions from the whey permeate to obtain a demineralized whey permeate. iii) Sialyllactose is separated by subjecting the demineralized whey permeate to a macroporous or gel-type anion exchange resin and subsequently eluting sialyl lactose from the macroporous or gel-type anion exchange resin with an acidic salt solution. iv) subjecting the separated sialic acid lactose to a demineralization step, and v) Add the demineralized sialylated lactose to an oligogalactose composition containing at least 35 wt% of oligogalactose other than lactose to form the oligogalactose formulation, or add the demineralized sialylated lactose to a lactose source and convert the lactose into oligogalactose using β-galactosidase.

2. The method of claim 1, wherein, Based on dry matter, this galactooligosaccharide preparation contains 40-90 wt%, preferably 50-70 wt%, of galactooligosaccharides other than lactose.

3. The method according to claim 1 or 2, wherein, Based on dry matter, this galactooligosaccharide formulation contains 0.2-2.0 wt%, preferably 0.4-1.0 wt%, of sialylated lactose.

4. The method according to any one of the preceding claims, wherein, Based on the total weight of oligosaccharides other than lactose, the galactooligosaccharide preparation contains 0.2-5.0 wt%, preferably 0.3-4.0 wt%, more preferably 0.3-3.0 wt%, even more preferably 0.4-2.0 wt%, and most preferably 0.5-1.0 wt% sialylated lactose.

5. The method according to any one of the preceding claims, wherein, This sialyl lactose is a combination of 3'-sialyl lactose and 6'-sialyl lactose.

6. The method according to any one of the preceding claims, wherein, Step ii) includes electrodialysis.

7. The method according to any one of the preceding claims, wherein, Step ii) includes a cation exchange step in which calcium ions are replaced by monovalent cations, an anion exchange step in which phosphate ions are replaced by monovalent cations, and additional steps in which monovalent ions are removed.

8. The method according to claim 7, wherein, The additional step in removing monovalent ions involves membrane filtration using membranes with a molecular weight cutoff of 200-300 Da or 400-2500 Da.

9. The method according to claim 7, wherein, The additional steps for removing monovalent ions involve cation and anion exchange steps.

10. The method according to any one of the preceding claims, wherein, The macroporous or gel-type anion exchange resin in step iii) has a moisture content of more than 45%, more preferably between 50% and 70%, and is in the form of free alkali.

11. The method according to any one of the preceding claims, wherein, The demineralized sialic acid lactose was added to a lactose source and the lactose was converted into galacto-oligosaccharides using a microbial β-galactosidase derived from the group consisting of: Bacillus circolithus, Aspergillus oryzae, Kluyveromyces marxi, Kluyveromyces fragilis, Lactobacillus monotypica, Lactobacillus fermentum and terrestrial Cryptococcus terrestrialus, with Bacillus circolithus being preferred.

Citation Information

Patent Citations

  • Oligosaccharide mixture

    WO2006087391A1

  • Dairy product and process

    WO2018020473A1

  • Method for preparing GOS-preparation with beta-galactosidase from cryptococcus terrestris, GOS preparations obtainable thereby and uses thereof

    WO2020141032A1